Heparan sulfate antibodies applications guide
![](/46/pdcnewsitem/04/28/92/amsbiopr178-image.jpg)
New 24-page guide that brings together applications, protocols, results and citations for researchers.
Amsbio has produced a new 24-page guide that brings together applications, protocols, results and citations to provide an informative resource for researchers using heparan sulfate antibodies.
Heparan Sulfate (HS) is synthesized as the glycosaminoglycan (GAG) component of heparan sulfate proteoglycans (HSPGs). It is expressed on the cell surface of virtually all cell types and basement membranes. It displays specific interactions with many biologically active proteins and, thus is involved in many important biological processes. Many researchers are interested in examining the dynamic distribution of HSPG in tissues and also analyzing HS structures to elucidate the biological functions of HSPG. The non-immunogenic character of HS makes this type of antibody difficult to raise, so the few hybridoma-derived mouse anti-HS antibodies such as JM403, 10E4 and 3G10 are valuable tools for HS research. Using multiple HS antibodies that recognize subtle differences in HS patterning can be useful in applications such as flow cytometry allowing multiple cell types to be directly compared.
Amsbio offers a suite of high quality heparan sulfate antibodies from the important clones F69-3G10, F58-10E4 and JM403. These antibodies are ideal for targeted binding of HS for HSPG research and provide a range of anti-HS antibodies recognizing distinct HS substructures, which have been well-characterized in previous studies. The guide provides an informative introduction to applications of JM403, 10E4 and 3G10 Heparan Sulfate antibodies; including use of the 10E4 and JM-403 clones together in ELISA to detect or measure HS. GAGs are not species-specific, so in common with AMSBIO’s other GAG antibodies, the clones featured in this guide react across a wide range of species.
Johan van der Vlag, Associate Professor at Radboud University Medical Center, Nijmegen commented: “I am extremely happy to see that our JM403 clone is commercially available to serve the scientific community that studies the role of GAGs in normal physiology and pathology. Since we only want to licence our antibody to a company that is dedicated to glycobiology and in particular GAGs, AMSBIO was our only choice.”
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance